إعلان
إعلان
BMRN
BioMarin Pharmaceuticals Inc
61.28
USDبرعاية
+1.21
+2.02%
٠٧ يناير, ١٦:٠٠ UTC -5
مغلق
بعد الإغلاق
61.03
-0.25
-0.41%
تقارير أرباح BMRN
النسبة الإيجابية المفاجئة
BMRN تفوق 29 من 40 آخر التقديرات.
73%
التقرير التالي
بيانات التقرير القادم
١٧ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$838.15M
/$0.86
التغير الضمني من Q3 25 (Revenue/ EPS)
+7.99%
/-637.50%
التغير الضمني من Q4 24 (Revenue/ EPS)
+12.16%
/+34.38%
BioMarin Pharmaceuticals Inc earnings per share and revenue
On ٢٧ أكتوبر ٢٠٢٥, BMRN reported earnings of -0.16 USD per share (EPS) for Q3 25, missing the estimate of 0.37 USD, resulting in a -142.18% surprise. Revenue reached 776.13 مليون, compared to an expected 796.24 مليون, with a -2.53% difference. The market reacted with a +1.56% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 27 المحللين forecast an EPS of 0.86 USD, with revenue projected to reach 838.15 مليون USD, implying an نقصان of -637.50% EPS, and زيادة of 7.99% in Revenue from the last quarter.
الأسئلة الشائعة
What were BioMarin Pharmaceuticals Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, BioMarin Pharmaceuticals Inc reported EPS of -$0.16, missing estimates by -142.18%, and revenue of $776.13M, -2.53% below expectations.
How did the market react to BioMarin Pharmaceuticals Inc's Q3 2025 earnings?
The stock price moved up 1.56%, changed from $52.67 before the earnings release to $53.49 the day after.
When is BioMarin Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for ١٧ فبراير ٢٠٢٦.
What are the forecasts for BioMarin Pharmaceuticals Inc's next earnings report?
Based on 27
المحللين, BioMarin Pharmaceuticals Inc is expected to report EPS of $0.86 and revenue of $838.15M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان